Inhibikase Therapeautics has received FDA approval to begin a Phase II trial of a compound called IkT-001. This compound is intended to clear the body of JC virus, which is the virus that causes PML. PML is the serious brain infection which has been seen in patients on the MS medication called Tysabri. This study is primarily a safety and dosing study in a small number of patients who are receiving Tysabri.

Although the IMSMP is not participating in this small study at this time, we will be following the research closely and share information as it becomes available.